mesothelioma cancer Topic Hollis-eden Pharmaceuticals Presents Positive Data With Apoptone(tm) In Preclinical Bone Model Of Late-stage Prostate Cancer mesothelioma asbestos mesothelioma lung cancer mesothelioma symptoms |

Latest Data

New Women, Smoking, And Heart Disease: Toenails Tell The Tale
Topic Cancer Risk Soars In Hiv-infected People: Study (reuters)
Update Brachytherapy Vs. Cryoablation In The Treatment Of Prostate Cancer
Current Initial Colonoscopy Key To Cancer Detection (healthday)
Comments Requested Sound Pharmaceuticals Files Second Ind With The Fda For The Prevention Of Chemotherapy Induced Hearing Loss In Advanced Stage Cancer
Join The Fight Against Cancer Radiation, Chemo Costs Drive Cancer Spending In U.s. (reuters)
Updated New Cyberknife Technologies Demonstrate Dramatic Reduction In Treatment Times
Important First Anniversary Of England’s Smokefree Law Shows Public Ready To Accept Even Stronger Tobacco Control Measures
Comments Requested Sunlight Helps Put Lung Cancer In The Shade (healthday)
Subject Allos Therapeutics Initiates Phase 2b Study Of Pdx In Patients With Non-small Cell Lung Cancer

« Current Einstein Researcher Receives $100,000 Grant For Lung Cancer Research | Main | Comments Requested Have A Smoke Free Holiday »

Topic Hollis-eden Pharmaceuticals Presents Positive Data With Apoptone(tm) In Preclinical Bone Model Of Late-stage Prostate Cancer

By admin2 | May 10, 2008

Medical Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, announced the presentation today of positive data from a preclinical study with APOPTONE™ (HE3235), its lead investigational drug candidate for cancer.
(Link)